| 117 wileyonlinelibrary.com/journal/bdi 1 | INTRODUC TI ON Older adults with bipolar disorder (OABD), generally regarded as age 60 years or over, represent 6% of geriatric psychiatry outpatient visits and 10% of geriatric psychiatry inpatients. 1 OABD is expected to comprise 50% of all cases of bipolar disorder by 2030. 2 Despite these significant numbers, international guidelines for the treatment of bipolar disorders have generally Objectives: Despite the growing numbers and proportion of older adults with bipolar disorder (OABD), there are very limited guidelines for the use of lithium with its double-edged potential for effectiveness and toxicity in this population. The primary aims of this Delphi survey were: (a) To determine the place of lithium among the preferred choices for maintenance treatment of OABD. (b) To provide detailed clinical guidelines for the safe and effective use of lithium in OABD. Methods: In the face of limited evidence, the Delphi survey method was used to achieve consensus by a group of 25 experts in OABD from nine countries. An oversight committee monitored and analyzed the results of each survey and formulated more focused questions with each subsequent iteration. Results: A 100% response rate was achieved for all three iterations of the survey. Lithium was the preferred choice for maintenance monotherapy in OABD. Serum levels of 0.4-0.8 mmol/L were recommended for ages 60-79 and serum levels of 0.4-0.7 mmol/L were recommended for ages 80 and over. Specific recommendations achieved consensus for second line monotherapy as well as for other drugs to be used in combination with lithium if necessary. Guidelines for routine monitoring of lithium in OABD were provided for laboratory investigations and clinical assessments.
not considered the specific management needs associated with OABD to date. 3 Based on a recent review of clinical practice guidelines (CPGs) and pharmaco-epidemiological data for all ages, lithium remains the first-line treatment for maintenance monotherapy despite the availability of several other choices for mood stabilization. [4] [5] [6] Treatment with lithium has been shown to reduce the risk of suicide 7, 8 and psychiatric admissions. 4 Emerging epidemiological and neurophysiological evidence suggests that lithium may have neuroprotective properties and reduce the risk of dementia 9, 10 and conceivably of cancer. 11 The results of neuroimaging studies have suggested that adults with bipolar disorder treated with lithium have better preserved cortical gray matter volume. 12, 13 Notably, OABD who were using lithium reported positive attitudes toward treatment. 14 On the other hand, lithium, just like all of the other mood stabilizers including antipsychotic agents, represents a double-edged sword for older adults. One concern has been its possible role in increasing the risk of chronic renal failure 15, 16 although there is also considerable recent epidemiological evidence that the risk is not as concerning as originally considered. 17 Other concerns include hypothyroidism, 18 hypercalcemia, 19 neurotoxicity, 20 and parkinsonism. 21 As the cohort of bipolar patients successfully maintained on lithium reaches their 70's and 80's, the age associated decrease in renal clearance may lead to higher lithium levels. This in turn leads to increased risk of side effects and outright toxicity if typical adult doses are not lowered. 20, 22 Several commonly used drugs in older adults, such as diuretics, ACE Inhibitors and non-steroidal anti-inflammatory drugs, can interact with lithium and cause higher serum levels, thereby increasing the risk of toxicity. 23 Furthermore, symptoms of toxicity (eg, tremor, gastrointestinal upset, and neurological disturbance) can be misinterpreted as other conditions commonly seen in later life, such as parkinsonism or dementia. 21 A "prescribing cascade" may ensue, 24 with additional medications introduced unnecessarily to assist in the management of the observed symptoms (eg, dopaminergic agents, cognitive enhancers, and gastrointestinal drugs). Clearly, more evidence and guidelines are needed that balance the risks and benefits of lithium use in OABD. 25, 26 The first randomized control study of lithium for OABD was only recently published. 27 The investigators compared the efficacy of lithium and divalproex in older adults for acute mania and mixed presentations, but not for maintenance therapy. Both drugs were shown to be efficacious and well tolerated, although lithium was associated with greater reduction in mania scores. While the evidence for its effectiveness remains high, the use of lithium in OABD has been declining compared to atypical antipsychotic agents and divalproex-a phenomenon for which there is no good supportive evidence. 28, 29 This increasing reluctance to prescribe lithium in OABD is most likely due to concerns about its toxicity, limited experience of younger clinicians with the use of lithium, and the impact of pharmaceutical marketing. 29 The most recent reviews of CPGs on the use of lithium for all ages recommend a target maintenance therapeutic serum level range of 0.6-0.8 mmol/L. The recently recommended therapeutic range is lower than the ones provided by most laboratories around the world which do not take into account the age of patients, phase of illness, or medical comorbidities. Malhi et al 6 have summarized the limited recommendations in CPGs for older adults which are not detailed.
Their recommended therapeutic range was 0.6-0.8 mmol/L but reported other ranges that varied from 0.4 to 1.3 mmol/L. Moreover, they noted that one of the limitations of CPGs is the lack of sensitivity to real world presentations. 6 In the face of compelling evidence for the effectiveness of lithium in bipolar disorder and its potential for neuroprotection combined with the lack of specific and detailed guidelines for its use in OABD, the ISBD task force on OABD conducted a Delphi survey of maintenance treatment for lithium in older adults in order to provide better direction for clinicians on the safety and effectiveness of lithium use in this vulnerable population. This survey focused on the question of maintenance therapy in OABD because of the clinical concern that the large cohort of adults who has been maintained on mood stabilizers for many years are now reaching old age. This study aims to fill the gap in data for this phase of treatment in OABD.
Clinical experience also suggests that lithium toxicity may be missed in older adults and that the "therapeutic" range for lithium reported by most labs could be misleading and lead to a false sense of "safe practice," especially to clinicians with limited experience in the use of lithium in OABD.
The primary aims of the survey were:
1. To determine the place of lithium among the preferred choices for maintenance treatment of OABD.
2. To provide clinical guidelines for the safe and effective use of lithium in OABD.
| ME THODS

| Study Design and Procedure
In the face of very limited systematic evidence for maintenance treatment in OABD, the Delphi method was chosen as a technique for obtaining consensus from a group of experts. Such panels generally consist of 10-25 experts. 30 The Delphi method has been used since the 1950's as a means of achieving consensus of expert opinion on a wide range of real-world knowledge. 31 It consists of a series of surveys where each wave represents a refinement of the previous one through a systematic process of feedback from the group. 30 This leads to a progressive move toward consensus. 30, 31 This is viewed as a type of "virtual meeting" that anonymizes the experts to each other and facilitates independent thought and the gradual formation of a considered opinion through a systematic process of communication and feedback. 30 An oversight committee is commonly set up to monitor unintentional bias. Because of the interest in correcting a perceived loss of confidence in the use of lithium in OABD, the potential bias in this initiative needed checks and balances. Without more valid evidence for lithium use in OABD, a systematic approach to expert consensus is the best way of providing direction to clinicians-perhaps enhancing the current clinical practice guidelines (CPG's) whose methodology varies considerably. 6 Three iterations, not more than 15-20 minutes in length, were sent electronically to each expert at approximately 1-month intervals (see Supporting information S1, S2, S3). All questions were The questions separated the recommendations into two broad age groups within OABD, ages 60-79 and 80 years, or over. Each survey asked the experts to comment on the items presented and provide a brief rationale for each answer. Participants were given opportunities to identify other areas of concern or controversy.
Each iteration was reviewed by an oversight committee (KS, OA, NH, AS, SS, AD, MS). The members of the oversight committee were also respondents in the survey. A cumulative impression of the group judgment for each item was presented by the oversight committee to the experts for the purpose of reviewing or revising their answers. The next iteration was then sent to all participants with each iteration comprised of questions that narrowed the focus based on previous responses. These iterations continued until consensus was reached (at least 80% agreement for each item) or the pre-set limit of three iterations elapsed, in which case non-consensus items were identified.
A flow chart describing the Delphi Method is presented in 
| Participants
An invitation to participate on the panel was extended to all the physician members of the ISBD OABD task force. This proved to be an excellent convenience sample from which to identify the best available internationally representative experts in this clinical arena.
Members of the task force were then asked to nominate other potential experts for inclusion on the panel. Twenty-seven experts were invited to take part in the Delphi survey. One did not respond to two invitations and another reported limited experience with OABD.
This left an expert group of 25 psychiatrists, 23 of whom identified themselves as geriatric psychiatrists and two as general psychiatrists with expertise in bipolar disorders. Table S4 summarizes the list of the experts involved in this survey and their countries of origin.
| RE SULTS
| Response rate
A complete response rate of 100% was achieved for all three iterations of the survey.
| Preferred choice for the maintenance of OABD
There was 100% consensus that lithium should be the drug of choice for maintenance monotherapy in OABD. Second line medications considered appropriate for monotherapy maintenance of OABD included lamotrigine, olanzapine, quetiapine, and valproate (See Table 1 ). No consensus was achieved regarding order of preference and hence the results of this question were reported as a group of optional choices listed in alphabetical order.
If maintenance of OABD with lithium requires adjunctive treatment, the following group of medications were recommended (once Recommendations for maintenance therapy for older adults with bipolar disorder (OABD) can be seen in Table 1 . Table 2 shows the therapeutic ranges of the serum concentration of lithium reported by the local laboratories used by the expert panelists. We requested this information to determine the current practice of laboratories in reporting the therapeutic range for serum lithium levels and to ascertain whether local laboratories provided separate guidelines for older adults. The most common level at the lower limit of the therapeutic range was 0.6 mmol/L (45%) while the most common level for upper limit was 1.2 mmol/L (60%). The current ranges reported by the labs are well above the range recommended by the experts and by recent CPG's for all adults. None of the labs reported a separate therapeutic range for older adults.
A summary of the consensus recommendations regarding the routineassessment of OABD receiving maintenance treatment with lithium can be seen in Table 3 . On that basis, it is recommended that OABD maintained on lithium should be assessed by a clinician at least every 6 months. Table 4 describes the expert consensus regarding the common signs of lithium toxcity among OABD.
| FURTHER RE S E ARCH
From comments received, experts suggested that further research is needed in OABD on the following:
Lithium's long-term effects on renal function and specifically
the concern about chronic renal failure 2. Lithium's and the atypical antipsychotics' effect on metabolic 
| D ISCUSS I ON
The results of this survey indicate that lithium remains the preferred choice of experts for mood stabilization during the maintenance phase of OABD. This recommendation must be viewed in the context of a significant and steady decline in use of lithium in this population, likely as a result of excessive anxiety about its safety profile in later life and the lack of pharmaceutical marketing. Hence these findings should provide some reassurance and guidance for clinicians to be more confident in their use of lithium in older adults. The well below those recommended by others, implying that our experts believe that a lower concentration of lithium may be more effective in later than early life, or that concerns about adverse effects demand greater caution when using lithium in older age. Some experts seemed to favor slightly higher serum lithium levels for Bipolar I patients but this did not achieve consensus. Increased efforts should be made to have laboratories report levels specifically for older adults that are in keeping with those recommended by clinical practice guidelines and by this survey. Certainly, the current therapeutic range for lithium levels reported by laboratories is much higher than is recommended by the most recent clinical practice guidelines 6, 33 and the results of this survey for OABD. This current practice by local laboratories puts older adults at risk of lithium toxicity and adds urgency to this clinical issue. Providing separate more appropriate therapeutic ranges of serum lithium levels for older adults should help to minimize the risk of toxicity in this vulnerable population. 20 With regard to lithium administration, the experts did not reach consensus on the value of twice compared to once daily dosing. The uncertainty in the literature on this point was reflected by the fact that some experts gave the same reason (less stress on the kidneys) for both options. The majority favored once daily dosing but this did not reach the consensus threshold. and not simply the opinion of the OABD task force members.
Lessons learned from the use of a Delphi survey include the need to remain focused on specific goals and objectives while avoiding excessive time and energy on controversial areas that are unlikely to achieve consensus. Specifically, we avoided a focus on the controversial area of lithium and renal function and limited our focus to the specific place and use of lithium in the maintenance treatment of OABD. We also refrained from drilling down on the other recommended mood stabilizers.
The successful recruitment of experts was done by personal connections as far as possible with individualized invitations rather than "cold call" emailing that is much less likely to attract participation.
Utilizing an existing structure, such as the OABD task force, from which to recruit experts ensured a high degree of interest and motivation to participate in a survey that may take three over four iterations. The use of brief questionnaires, timely feedback and short intervals between iterations helped to maintain motivation and interest in the study and continued participation in the survey on repeated iterations. Our 100% response rate for all three iterations is a testament to those factors and avoided the potential for a low response rate with multiple iterations, one of the common limitations of a Delphi survey.
It was important to identify quickly those issues for which consensus was not possible or likely, and not try to force consensus. The oversight team helped to formulate the next iteration of questions designed to sharpen the focus of the survey and obtain as much consensus as possible. It made most sense to use the Discussion to elaborate on the issues where there was no consensus. Use of the oversight team to review results objectively and avoid unintended guidance of responses due to preconceived ideas was critical.
In the face of very limited published data to inform clinical practice, it has been argued that consensus expert opinion must be explicitly recognized by CPG authoring groups. 33 Given the impact that CPG's have on clinical practice, this is an important consideration for maintenance treatment of OABD. Expert opinion is based on a combination of vast clinical experience and accumulated knowledge from a wide range of sources which should strengthen the credibility of CPGs which tend to focus on published "evidence." A "hybrid" CPG that includes both published data and expert opinion may be more relevant and practical for clinicians. 33 The recent CANMAT and ISBD bipolar disorder guidelines provide an example of such a hybrid section on older adults but still lack specifics with regard to therapeutic serum levels of lithium and relevant laboratory and clinical investigations for OABD. 36 Osvaldo P. Almeida https://orcid.org/0000-0002-8689-6199
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